retatrutide mechanism triple agonist glp-1 gip glucagon Schematic illustration of monoagonists, dual agonists and retatrutide mechanism triple agonist glp-1

Statement on a nonproprietary name adopted by the USAN Council: Eloralintide

LIV Body's brand positioning is particularly targeted toward people who are already physically active and want to address a metabolic component that's resisting their efforts

COVID-19 and diabetes

Hospitalization , feeding-tube placement, or other intensive medical interventions for persistent vomiting or dehydration

However, clinicians must remain cautious about side effects, including urinary tract infections, genital mycotic infections, and rare but serious cases of diabetic ketoacidosis

Overall, GLP-1 receptor agonists are not replacements for existing treatments such as naltrexone in alcohol use disorder